IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today released its 2025 Corporate Responsibility Report, highlighting progress against the company’s goals and commitments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728755319/en/

2025 IDEXX Corporate Responsibility Report

2025 IDEXX Corporate Responsibility Report

“At IDEXX, corporate responsibility is central to how we create long-term value,” said Mike Erickson, IDEXX President and Chief Executive Officer. “The progress reflected in this report is the result of sustained investments in innovation, our people, and capabilities that support our customers every day. These priorities are deeply connected to our business strategy and purpose, strengthening our company today while positioning us for future innovation and growth.”

The Care We Advance

Veterinary medicine is undergoing rapid transformation as advances in science and technology enable earlier detection, faster diagnosis, and deeper insights into disease. IDEXX is helping lead that evolution through innovations that bring screening and diagnosis closer together and expand access to advanced diagnostics. Over the past year, IDEXX:

  • Significantly advanced its innovation portfolio by launching or achieving launch readiness for multiple solutions, led by the IDEXX Cancer Dx™ Panel with canine lymphoma detection and new fine needle aspirate (FNA) cytology capabilities for mast cell tumors on the IDEXX inVue Dx™ Cellular Analyzer, helping address one of veterinary medicine’s greatest unmet needs.
  • Raised the standard for diagnostic imaging with the ImageVue™ DR50 Plus Digital Imaging System, combining advanced AI and the industry’s lowest radiation dose to help protect veterinary teams.
  • Helped enable access to care for more than 45,000 animals in underserved communities in 2025, bringing the cumulative number supported through global social initiatives since 2022 to more than 749,000 animals.

The People We Support

Innovation begins with people. IDEXX continues to invest in the capabilities, development, and engagement of its workforce, recognizing that strong teams are essential to advancing science, serving customers, and supporting long-term growth. Notable highlights include:

  • Received recognition as a top disability-inclusive business from the Disability Index.
  • Logged 121,400 hours of learning and development, including 46,700 hours of STEM and AI learning.
  • Surpassed its employee volunteering goal with more than 24,000 logged volunteer hours, exceeding its annual goal of 15,000 hours.

The Planet We Share

As a global company, IDEXX remains focused on managing resources responsibly and reducing its environmental footprint. The company remains on track to meet its 2030 GHG emissions reduction goal and anticipates significant emissions reductions in the next few years. Progress in 2025 reflected continued investment in renewable electricity, operational efficiency, and initiatives designed to reduce waste and extend product life. Across its operations, IDEXX:

  • Signed its first virtual power purchase agreement (VPPA) in Europe, bringing the total to three VPPAs expected to source enough renewable electricity to cover 100% of IDEXX’s North American and European electricity consumption when they come online.
  • Continued the transition of its commercial fleet to hybrid and electric vehicle models, which represented approximately 42% of its fleet at year-end 2025.
  • Extended instrument life and improved reliability for customers by servicing more than 35,000 instruments and completing 85,000 point-of-service upgrades on select IDEXX instruments.

This Corporate Responsibility Report covers topics the company believes are relevant to our business and stakeholders. IDEXX uses well-established reporting standards generally aligned with frameworks, such as those released by the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-related Financial Disclosures (TCFD). Read the report here.

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

Media Relations
media@idexx.com

Investor Relations
investorrelations@idexx.com

Source: IDEXX Laboratories, Inc.

Released July 28, 2026